• Tuesday, Aug 04, 2020
  • Last Update : 02:36 am

India's Biocon secures approval use drug on coronavirus patients

  • Published at 09:12 pm July 11th, 2020
Biocon Ltd Chairman
FILE PHOTO: India's Biocon Ltd Chairman and Managing Director Kiran Mazumdar-Shaw speaks during the Forbes Global CEO Conference in Kuala Lumpur September 13, 2011 REUTERS

The randomised control trial indicated that all the patients treated with Itolizumab responded positively and recovered, says Biocon’s executive chairperson

India’s Biocon Ltd has received regulatory approval for its drug Itolizumab to be used on coronavirus infected patients suffering from moderate to severe respiratory distress, the biopharmaceutical company said in a statement on Saturday.

The drug, which is also used to cure the skin disease psoriasis, was cleared by the Drug Controller General of India (DCGI) for usage in India.

“The randomised control trial indicated that all the patients treated with Itolizumab responded positively and recovered,” said Kiran Mazumdar-Shaw, the firm’s executive chairperson.

The control group which did not receive Itolizumab unfortunately suffered deaths, she said, adding that the “first-in-class” drug will save lives and help reduce the mortality rate in India.

Clinical studies involving the drug are being closely watched as nations look for treatments for the disease that has infected over 820,000 people and killed over 22,000 in India.

India recorded 27,114 coronavirus cases in the last 24 hours. The South Asian country’s coronavirus case tally has made it the nation with the third-biggest outbreak, behind only the United States and Brazil in confirmed infections.

The DGCI earlier this month approved pharmaceutical firm Zydus Cadila to start phase one and phase two human clinical trials of its Covid-19 vaccine. Itolizumab is the second vaccine to gain approval after Hyderabad-based Bharat Biotech’s COVAXIN.

blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail